Jam

Haleon has broken ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility aims to accelerate new product development, enhance scientific capabilities, and serve as a global hub for oral health research. The center will foster collaboration and innovation, focusing on addressing unmet oral health needs and promoting sustainability. This investment supports Haleon’s mission to bring better everyday health to more consumers worldwide.

Elixxer Ltd. announces the upcoming resumption of trading following the revocation of a cease trade order. Key initiatives, including a new stock option plan, received shareholder approval at the AGM. The company has also strengthened its leadership with new CEO and CFO appointments and a refreshed Board of Directors. Strategic debt restructuring and bridge financing are in place. Elixxer is actively pursuing merger and acquisition opportunities and is involved in ongoing litigation regarding its investment in Freia Farmaceutici Srl.

Canada One Mining Corp. (TSXV: CONE) shareholders approved all resolutions at their 2025 AGM, including board appointments and auditor re-election. The company is also partnering with Rob Christl Consulting to enhance investor relations and broaden its market reach, with a C$2,500 monthly retainer and performance-based incentives.

Aranjin Resources Ltd. has appointed Thomas Wood as CEO, effective immediately. Wood brings extensive experience in economic policy, business strategy, and investment from both public and private sectors, including roles in the Australian Senate and managing mining investments. Matthew Wood will shift to Executive Chair. The company anticipates Wood’s leadership will drive growth, particularly for its Victory Project.

Permex Petroleum Corporation secured a US$2 million private placement of convertible debentures and warrants. The funds will bolster working capital for general operations and strategic initiatives. Each unit comprises a debenture with a 10% annual interest rate and common share purchase warrants. The financing is intended for accredited investors and closes after a five-day notice period.

United Microelectronics Corporation (UMC) exceeded market expectations with strong June 2025 net sales. This robust performance highlights UMC’s resilient operations and strategic position in the dynamic semiconductor market. The foundry giant’s growth, fueled by demand in AI, automotive, and IoT, signals a promising outlook for the second half of 2025.

Dream Vacations launches its 14th annual “Operation Vetrepreneur” contest, offering U.S. military veterans a chance to win a complimentary travel agency franchise. This year’s grand prize includes a franchise, a Carnival cruise for two, and comprehensive training. The contest aims to empower veterans with entrepreneurial opportunities, continuing a legacy of over $787,200 in gifted franchises since 2012. Applications are open until September 1, 2025.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

Honey Badger Silver Inc. successfully closed the first tranche of its private placement, raising approximately $2.01 million. The financing, involving non-flow-through units and flow-through shares, will fund exploration on properties in the Yukon, Northwest Territories, and Nunavut, as well as property advancement and acquisitions. Prominent investor Eric Sprott participated in the round.

QT Imaging Holdings, Inc. announced its 2025 virtual Annual Meeting of Stockholders, scheduled for August 19, 2025. Registered shareholders as of July 16, 2025, are eligible to vote. Details for the webcast are available in the proxy statement and on the company’s website. QT Imaging is an innovator in medical imaging technology, focusing on low-frequency sound waves for disease detection and treatment.